REDD1 deletion attenuates cancer cachexia in mice
Brian A. Hain, Haifang Xu, Ashley M. VanCleave, Bradley S. Gordon, Scot R. Kimball, David L. Waning
Abstract
Cancer cachexia is a debilitating and lethal consequence of many advanced cancers. REDD1, a negative regulator of mTORC1 activity, is an emerging target in cachexia. Our data show that skeletal muscle REDD1 expression is increased in LLC-induced cancer cachexia. Mice lacking REDD1 have attenuated skeletal muscle atrophy that is likely due to maintaining both protein synthesis and inhibiting protein degradation.
Topics & Concepts
CachexiaCancer cachexiaSkeletal musclemTORC1Muscle atrophyRegulatorCancerMedicineEndocrinologySarcopeniaAtrophyCancer researchInternal medicineBiologyPhosphorylationCell biologyBiochemistryProtein kinase BGeneMuscle Physiology and DisordersNuclear Structure and FunctionNutrition and Health in Aging